ALK and non-small cell lung carcinoma: In the phase II trial, 222 crizotinib-refractory ALK-positive NSCLC patients were randomized to brigatinib 90 mg/day (arm A) or 180 mg/day with a 7-day lead-in at 90 mg (arm B) (94), and updated results were recently presented (95).